Pursuing investment opportunities in biotechnology and pharmaceutical space.

Focus on financing activities (closed $36M Series B financing round in April 2014) and M&A activities (closed merger with Zalicus in July 2014, EPIRUS now traded on NASDAQ: EPRS)Direct tax optimization strategy and execution, including the formation of subsidiaries in Switzerland and Brazil and the transfer of EPIRUS IP to SwitzerlandRun Financial Planning and Analysis group, which develops and monitors departmental budgets, builds and maintains long-term financial models, supports M&A transactions, and contributes to investor outreach efforts and SEC filingsManage investor relations and corporate communications

Incorporated Epirus subsidiary in Brazil and negotiated agreements to direct clinical, regulatory, and commercial activities of Epirus and Brazil partnerWorked with private health insurance providers and government agencies in South Africa to evaluate biosimilar market potential and identify appropriate partnersEvaluated multiple partners and project financing opportunities in Russia

Developed, through partnerships or acquisitions, low-cost product options for under-served populations in Brazil, Russia, India, and Mexico.Evaluated low-cost market potential in the US and other developed markets.

Quantified low cost spinal implant product segment opportunities in Brazil, Russia, India, and Mexico and developed practical strategies for near term market entry.Worked with the spine team in India to source cement for use in local balloon kyphoplasty (BKP) procedures, create a physician and patient awareness plan for BKP, pursue official guidelines for treatment of vertebral compression fractures, and educate family doctors on spine pathologies and treatment options.Consolidated patient, procedure, and pricing data for major spine therapies across all countries.

Evaluated clinical, therapeutic, and market variables to forecast market demand for ataluren, PTC’s advanced drug candidate for the treatment of genetic diseases caused by nonsense mutations.Recommended infrastructure investments based on demand, costs, and PTC’s strategic and financial objectives.

Supported Board of Directors and CEO Staff in strategy planning and execution. Tracked industry trends, analyzed target companies, and supported deal execution and integration activities.Led financial analysis of diverse proposals in an accelerated divestiture of Amgen's Japan subsidiary. Managed due diligence in Tokyo and coordinated negotiation, signing, and closing activities.Led financial analysis, coordinated clinical negotiations, built and executed internal and external deal communications plan, and supported integration activities for acquisitions of Ilypsa and Alantos.Supported deal execution and integration activities for acquisitions of Avidia and Abgenix.

Developed data-driven solutions for major clients in healthcare, consumer goods, and beverage alcohol industries. Project experience in post-merger integration, brand investment optimization, sales operations, market research, and pricing.